Active Clinical Trials and Research Studies on EGIDs
Please click on the link to learn more details about the trial, its purpose, who may participate, locations, and phone numbers. Please seek advice from your medical teams about the clinical trials or studies you are interested in. The items are listed in date order & updated periodically:
ENGAGE – adults and adolescents who have EoG with or without EoD
Is eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD) affecting your daily life?
The below website link provides information about a clinical study, Engage, for adults and adolescents who have EoG with or without EoD. Currently, there is no suitable long-term treatment for EoG. Considering this gap in treatment, the Engage clinical research study aims to assess the safety and efficacy of a study drug in treating EoG in adults and adolescents.
Is eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD) affecting your daily life?
The below website link provides information about a clinical study, Engage, for adults and adolescents who have EoG with or without EoD. Currently, there is no suitable long-term treatment for EoG. Considering this gap in treatment, the Engage clinical research study aims to assess the safety and efficacy of a study drug in treating EoG in adults and adolescents.
DESTINY study for adults with HES Expand
To check eligibility take this survey
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy.
Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Study Start Date: June 2015
National Institute of Allergy and Infectious Diseases (NIAID)
How to Participate: NTC02523118
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
Study Start Date: December 2005
Children’s Hospital Medical Center, Cincinnati
How to Participate: NTC00267501